How might infant and paediatric immune responses influence malaria vaccine efficacy?

Parasite Immunology

Volumn 31, Issue 9, 2009, Pages 547-559

  Moormann, A M ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Infant immunity; Malaria; Vaccines

Indexed keywords

AS01 VACCINE; AS01E VACCINE; AS02 VACCINE; AS02D VACCINE; IMMUNOGLOBULIN G3 ANTIBODY; INSECTICIDE; MALARIA VACCINE; RABIES VACCINE; RTS,S VACCINE; UNCLASSIFIED DRUG; VACCINE;

ADJUVANT THERAPY; ANTIBODY TITER; ANTIGENICITY; CELL MEDIATED CYTOTOXICITY; CELLULAR IMMUNITY; CHILD; CLINICAL TRIAL; DENDRITIC CELL; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; ENVIRONMENTAL EXPOSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEALTH PROGRAM; HUMAN; HUMORAL IMMUNITY; HYPERGAMMAGLOBULINEMIA; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOPATHOLOGY; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFANT; INNATE IMMUNITY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTOPENIA; MALARIA; MORBIDITY; MORTALITY; NATURAL KILLER CELL; NATURAL KILLER T CELL; PARASITE; PLASMODIUM; PLASMODIUM FALCIPARUM; PREVENTIVE MEDICINE; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; REDUCTION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; VACCINATION;

AGE FACTORS; CHILD, PRESCHOOL; HUMANS; IMMUNE SYSTEM; INFANT; MALARIA; MALARIA VACCINES;

EID: 68949128627     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/j.1365-3024.2009.01137.x     Document Type: Review

References (117)

1. Maitland K Marsh K. Pathophysiology of severe malaria in children. Acta Trop 2004 90 : 131 140.
2. Clark IA Schofield L. Pathogenesis of malaria. Parasitol Today 2000 16 : 451 454.
3. Artavanis-Tsakonas K, Tongren JE Riley EM. The war between the malaria parasite and the immune system: immunity, immunoregulation and immunopathology. Clin Exp Immunol 2003 133 : 145 152.
4. Cohen S, Mc GI Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature 1961 192 : 733 737.
5. McGregor IA, Williams K Goodwin LG. Pyrimethamine and sulphadiazine in treatment of malaria. Br Med J 1963 2 : 728 729.
6. Good MF, Xu H, Wykes M Engwerda CR. Development and regulation of cell-mediated immune responses to the blood stages of malaria: implications for vaccine research. Annu Rev Immunol 2005 23 : 69 99.
7. Osier FH, Fegan G, Polley SD, et al. Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun 2008 76 : 2240 2248.
8. Schofield L Mueller I. Clinical immunity to malaria. Curr Mol Med 2006 6 : 205 221.
9. Vekemans J Ballou WR. Plasmodium falciparum malaria vaccines in development. Expert Rev Vaccines 2008 7 : 223 240.
10. Corran P, Coleman P, Riley E Drakeley C. Serology: a robust indicator of malaria transmission intensity? Trends Parasitol 2007 23 : 575 582.
11. Gray JC, Corran PH, Mangia E, et al. Profiling the antibody immune response against blood stage malaria vaccine candidates. Clin Chem 2007 53 : 1244 1253.
12. Omosun YO, Adoro S, Anumudu CI, et al. Antibody specificities of children living in a malaria endemic area to inhibitory and blocking epitopes on MSP-1 19 of Plasmodium falciparum. Acta Trop 2009 109 : 208 212.
13. Holder AA, Guevara Patino JA, Uthaipibull C, et al. Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria. Parassitologia 1999 41 : 409 414.
14. Filipe JA, Riley EM, Drakeley CJ, Sutherland CJ Ghani AC. Determination of the processes driving the acquisition of immunity to malaria using a mathematical transmission model. PLoS Comput Biol 2007 3 : e255.
15. Bouharoun-Tayoun H, Oeuvray C, Lunel F Druilhe P. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med 1995 182 : 409 418.
16. Hviid L. Naturally acquired immunity to Plasmodium falciparum malaria in Africa. Acta Trop 2005 95 : 270 275.
17. Tongren JE, Drakeley CJ, McDonald SL, et al. Target antigen, age, and duration of antigen exposure independently regulate immunoglobulin G subclass switching in malaria. Infect Immun 2006 74 : 257 264.
18. Kinyanjui SM, Bull P, Newbold CI Marsh K. Kinetics of antibody responses to Plasmodium falciparum-infected erythrocyte variant surface antigens. J Infect Dis 2003 187 : 667 674.
19. Lanzavecchia A, Bernasconi N, Traggiai E, Ruprecht CR, Corti D Sallusto F. Understanding and making use of human memory B cells. Immunol Rev 2006 211 : 303 309.
20. Nutt SL, Kallies A Belz GT. Blimp-1 connects the intrinsic and extrinsic regulation of T cell homeostasis. J Clin Immunol 2008 28 : 97 106.
21. Kimberley FC, Hahne M Medema JP. 'APRIL hath put a spring of youth in everything': relevance of APRIL for survival. J Cell Physiol 2009 218 : 1 8.
22. Dent AE, Bergmann-Leitner ES, Wilson DW, et al. Antibody-mediated growth inhibition of Plasmodium falciparum: relationship to age and protection from parasitemia in Kenyan children and adults. PLoS ONE 2008 3 : e3557.
23. McCallum FJ, Persson KE, Mugyenyi CK, et al. Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum. PLoS ONE 2008 3 : e3571.
24. Ockenhouse CF, Angov E, Kester KE, et al. Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. Vaccine 2006 24 : 3009 3017.
25. Polhemus ME, Magill AJ, Cummings JF, et al. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine 2007 25 : 4203 4212.
26. Bolad A, Nebie I, Cuzin-Ouattara N, Traore A, Esposito F Berzins K. Antibody-mediated in vitro growth inhibition of field isolates of Plasmodium falciparum from asymptomatic children in Burkina Faso. Am J Trop Med Hyg 2003 68 : 728 733.
27. Perraut R, Marrama L, Diouf B, et al. Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village. J Infect Dis 2005 191 : 264 271.
28. O'Donnell RA, de Koning-Ward TF, Burt RA, et al. Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria. J Exp Med 2001 193 : 1403 1412.
29. Egan AF, Morris J, Barnish G, et al. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. J Infect Dis 1996 173 : 765 769.
30. Branch OH, Oloo AJ, Nahlen BL, Kaslow D Lal AA. Anti-merozoite surface protein-1 19-kDa IgG in mother-infant pairs naturally exposed to Plasmodium falciparum: subclass analysis with age, exposure to asexual parasitemia, and protection against malaria. V. The Asembo Bay Cohort Project. J Infect Dis 2000 181 : 1746 1752.
31. Okech BA, Corran PH, Todd J, et al. Fine specificity of serum antibodies to Plasmodium falciparum merozoite surface protein, PfMSP-1(19), predicts protection from malaria infection and high-density parasitemia. Infect Immun 2004 72 : 1557 1567.
32. Heppner DG Jr., Kester KE, Ockenhouse CF, et al. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine 2005 23 : 2243 2250.
33. Genton B, Anders RF, Alpers MP Reeder JC. The malaria vaccine development program in Papua New Guinea. Trends Parasitol 2003 19 : 264 270.
34. Corran PH, O'Donnell RA, Todd J, et al. The fine specificity, but not the invasion inhibitory activity, of 19-kilodalton merozoite surface protein 1-specific antibodies is associated with resistance to malarial parasitemia in a cross-sectional survey in The Gambia. Infect Immun 2004 72 : 6185 6189.
35. John CC, Koech DK, Sumba PO Ouma JH. Risk of Plasmodium falciparum infection during a malaria epidemic in highland Kenya, 1997. Acta Trop 2004 92 : 55 61.
36. John CC, O'Donnell RA, Sumba PO, et al. Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa. J Immunol 2004 173 : 666 672.
37. Dent A, Malhotra I, Mungai P, et al. Prenatal malaria immune experience affects acquisition of Plasmodium falciparum merozoite surface protein-1 invasion inhibitory antibodies during infancy. J Immunol 2006 177 : 7139 7145.
38. Wykes M Good MF. Memory B cell responses and malaria. Parasite Immunol 2006 28 : 31 34.
39. Dorfman JR, Bejon P, Ndungu FM, et al. B cell memory to 3 Plasmodium falciparum blood-stage antigens in a malaria-endemic area. J Infect Dis 2005 191 : 1623 1630.
40. Moir S, Ho J, Malaspina A, et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med 2008 205 : 1797 1805.
41. Kassa D, Petros B, Mesele T, Hailu E Wolday D. Characterization of peripheral blood lymphocyte subsets in patients with acute Plasmodium falciparum and P. vivax malaria infections at Wonji Sugar Estate, Ethiopia. Clin Vaccine Immunol 2006 13 : 376 379.
42. Asito AS, Moormann AM, Kiprotich C, Ng'ang'a ZW, Ploutz-Snyder R Rochford R. Alterations on peripheral B cell subsets following an acute uncomplicated clinical malaria infection in children. Malar J 2008 7 : 238.
43. Elhassan IM, Hviid L, Satti G, et al. Evidence of endothelial inflammation, T cell activation, and T cell reallocation in uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg 1994 51 : 372 379.
44. Greenwood BM. Possible role of a B-cell mitogen in hypergammaglobulinaemia in malaria and trypanosomiasis. Lancet 1974 1 : 435 436.
45. Chene A, Donati D, Guerreiro-Cacais AO, et al. A molecular link between malaria and Epstein-Barr virus reactivation. PLoS Pathog 2007 3 : e80.
46. Donati D, Zhang LP, Chene A, et al. Identification of a polyclonal B-cell activator in Plasmodium falciparum. Infect Immun 2004 72 : 5412 5418.
47. Siegrist CA. The challenges of vaccine responses in early life: selected examples. J Comp Pathol 2007 137 (Suppl. 1 S4 S9.
48. Wilson CB Kollmann TR. Induction of antigen-specific immunity in human neonates and infants. Nestle Nutr Workshop Ser Pediatr Program 2008 61 : 183 195.
49. Good MF Doolan DL. Immune effector mechanisms in malaria. Curr Opin Immunol 1999 11 : 412 419.
50. Plebanski M Hill AV. The immunology of malaria infection. Curr Opin Immunol 2000 12 : 437 441.
51. Baird JK. Age-dependent characteristics of protection v. susceptibility to Plasmodium falciparum. Ann Trop Med Parasitol 1998 92 : 367 390.
52. Walther M, Woodruff J, Edele F, et al. Innate immune responses to human malaria: heterogeneous cytokine responses to blood-stage Plasmodium falciparum correlate with parasitological and clinical outcomes. J Immunol 2006 177 : 5736 5745.
53. Seder RA, Darrah PA Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008 8 : 247 258.
54. Venturi V, Price DA, Douek DC Davenport MP. The molecular basis for public T-cell responses? Nat Rev Immunol 2008 8 : 231 238.
55. Hammarlund E, Lewis MW, Hansen SG, et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003 9 : 1131 1137.
56. Greenwood BM, Fidock DA, Kyle DE, et al. Malaria: progress, perils, and prospects for eradication. J Clin Invest 2008 118 : 1266 1276.
57. Lanzavecchia A Sallusto F. Understanding the generation and function of memory T cell subsets. Curr Opin Immunol 2005 17 : 326 332.
58. Williams MA Bevan MJ. Effector and memory CTL differentiation. Annu Rev Immunol 2007 25 : 171 192.
59. Yun TJ Bevan MJ. The Goldilocks conditions applied to T cell development. Nat Immunol 2001 2 : 13 14.
60. John CC, Moormann AM, Sumba PO, Ofulla AV, Pregibon DC Kazura JW. Gamma interferon responses to Plasmodium falciparum liver-stage antigen 1 and thrombospondin-related adhesive protein and their relationship to age, transmission intensity, and protection against malaria. Infect Immun 2004 72 : 5135 5142.
61. Moormann AM, Sumba PO, Tisch DJ, et al. Stability of interferon-gamma and interleukin-10 responses to Plasmodium falciparum liver stage antigen-1 and thrombospondin-related adhesive protein immunodominant epitope peptides in a highland population from western Kenya. Am J Trop Med Hyg 2009 (in press).
62. Huaman MC, Martin LB, Malkin E, et al. Ex vivo cytokine and memory T cell responses to the 42-kDa fragment of Plasmodium falciparum merozoite surface protein-1 in vaccinated volunteers. J Immunol 2008 180 : 1451 1461.
63. Riley JK Yokoyama WM. NK cell tolerance and the maternal-fetal interface. Am J Reprod Immunol 2008 59 : 371 387.
64. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol 2007 7 : 379 390.
65. Angelone DF, Wessels MR, Coughlin M, et al. Innate immunity of the human newborn is polarized toward a high ratio of IL-6/TNF-alpha production in vitro and in vivo. Pediatr Res 2006 60 : 205 209.
66. van den Eijnden DH, Blanken WM van Vliet A. Branch specificity of beta-D-galactosidase from Escherichia coli. Carbohydr Res 1986 151 : 329 335.
67. Chelvarajan RL, Collins SM, Doubinskaia IE, et al. Defective macrophage function in neonates and its impact on unresponsiveness of neonates to polysaccharide antigens. J Leukoc Biol 2004 75 : 982 994.
68. Bettelli E, Korn T, Oukka M Kuchroo VK. Induction and effector functions of T(H)17 cells. Nature 2008 453 : 1051 1057.
69. Khader SA Cooper AM. IL-23 and IL-17 in tuberculosis. Cytokine 2008 41 : 79 83.
70. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007 8 : 942 949.
71. Dumoutier L, Van Roost E, Colau D Renauld JC. Human interleukin-10- related T cell-derived inducible factor: molecular cloning and functional characterization as an hepatocyte-stimulating factor. Proc Natl Acad Sci USA 2000 97 : 10144 10149.
72. Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Karow M Flavell RA. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 2007 27 : 647 659.
73. Couper KN, Blount DG, Wilson MS, et al. IL-10 from CD4CD25Foxp3CD127 adaptive regulatory T cells modulates parasite clearance and pathology during malaria infection. PLoS Pathog 2008 4 : e1000004.
74. Todryk SM, Bejon P, Mwangi T, et al. Correlation of memory T cell responses against TRAP with protection from clinical malaria, and CD4 CD25 high T cells with susceptibility in Kenyans. PLoS ONE 2008 3 : e2027.
75. Godfrey WR, Spoden DJ, Ge YG, et al. Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. Blood 2005 105 : 750 758.
76. Blackburn SD, Shin H, Haining WN, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009 10 : 29 37.
77. Ha SJ, West EE, Araki K, Smith KA Ahmed R. Manipulating both the inhibitory and stimulatory immune system towards the success of therapeutic vaccination against chronic viral infections. Immunol Rev 2008 223 : 317 333.
78. Fife BT Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 2008 224 : 166 182.
79. Korbel DS, Finney OC Riley EM. Natural killer cells and innate immunity to protozoan pathogens. Int J Parasitol 2004 34 : 1517 1528.
80. Stevenson MM Riley EM. Innate immunity to malaria. Nat Rev Immunol 2004 4 : 169 180.
81. Artavanis-Tsakonas K, Eleme K, McQueen KL, et al. Activation of a subset of human NK cells upon contact with Plasmodium falciparum-infected erythrocytes. J Immunol 2003 171 : 5396 5405.
82. Uhrberg M, Valiante NM, Shum BP, et al. Human diversity in killer cell inhibitory receptor genes. Immunity 1997 7 : 753 763.
83. Arbour NC, Lorenz E, Schutte BC, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000 25 : 187 191.
84. Lyakh L, Trinchieri G, Provezza L, Carra G Gerosa F. Regulation of interleukin-12/interleukin-23 production and the T-helper 17 response in humans. Immunol Rev 2008 226 : 112 131.
85. Khayrullina T, Yen JH, Jing H Ganea D. In vitro differentiation of dendritic cells in the presence of prostaglandin E2 alters the IL-12/IL-23 balance and promotes differentiation of Th17 cells. J Immunol 2008 181 : 721 735.
86. Katamura K, Shintaku N, Yamauchi Y, et al. Prostaglandin E2 at priming of naive CD4+ T cells inhibits acquisition of ability to produce IFN-gamma and IL-2, but not IL-4 and IL-5. J Immunol 1995 155 : 4604 4612.
87. Splawski JB Lipsky PE. Prostaglandin E2 inhibits T cell-dependent Ig secretion by neonatal but not adult lymphocytes. J Immunol 1994 152 : 5259 5267.
88. Marodi L. Innate cellular immune responses in newborns. Clin Immunol 2006 118 : 137 144.
89. Todryk SM Urban BC. Dendritic cells in Plasmodium infection. Future Microbiol 2008 3 : 279 286.
90. Lauzon NM, Mian F, MacKenzie R Ashkar AA. The direct effects of Toll-like receptor ligands on human NK cell cytokine production and cytotoxicity. Cell Immunol 2006 241 : 102 112.
91. Krishnegowda G, Hajjar AM, Zhu J, et al. Induction of proinflammatory responses in macrophages by the glycosylphosphatidylinositols of Plasmodium falciparum: cell signaling receptors, glycosylphosphatidylinositol (GPI) structural requirement, and regulation of GPI activity. J Biol Chem 2005 280 : 8606 8616.
92. Nebl T, De Veer MJ Schofield L. Stimulation of innate immune responses by malarial glycosylphosphatidylinositol via pattern recognition receptors. Parasitology 2005 130 (Suppl. S45 S62.
93. Parroche P, Lauw FN, Goutagny N, et al. Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9. Proc Natl Acad Sci USA 2007 104 : 1919 1924.
94. Gerosa F, Baldani-Guerra B, Lyakh LA, et al. Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells. J Exp Med 2008 205 : 1447 1461.
95. Loharungsikul S, Troye-Blomberg M, Amoudruz P, et al. Expression of toll-like receptors on antigen-presenting cells in patients with falciparum malaria. Acta Trop 2008 105 : 10 15.
96. McCall MB, Netea MG, Hermsen CC, et al. Plasmodium falciparum infection causes proinflammatory priming of human TLR responses. J Immunol 2007 179 : 162 171.
97. Dalpke A Heeg K. Signal integration following Toll-like receptor triggering. Crit Rev Immunol 2002 22 : 217 250.
98. Hartgers FC, Obeng BB, Voskamp A, et al. Enhanced TLR responsiveness associated with MAPK activation in Plasmodium falciparum-infected children. Infect Immun 2008 76 : 5149 5157.
99. Adegnika AA, Kohler C, Agnandji ST, et al. Pregnancy-associated malaria affects toll-like receptor ligand-induced cytokine responses in cord blood. J Infect Dis 2008 198 : 928 936.
100. King CL, Malhotra I, Wamachi A, et al. Acquired immune responses to Plasmodium falciparum merozoite surface protein-1 in the human fetus. J Immunol 2002 168 : 356 364.
101. Moorthy VS, Good MF Hill AV. Malaria vaccine developments. Lancet 2004 363 : 150 156.
102. Good MF. Vaccine-induced immunity to malaria parasites and the need for novel strategies. Trends Parasitol 2005 21 : 29 34.
103. Greenwood B. Malaria vaccines. Evaluation and implementation. Acta Trop 2005 95 : 298 304.
104. Bejon P, Lusingu J, Olotu A, et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 2008 359 : 2521 2532.
105. Abdulla S, Oberholzer R, Juma O, et al. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N Engl J Med 2008 359 : 2533 2544.
106. Stoute JA, Gombe J, Withers MR, et al. Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. Vaccine 2007 25 : 176 184.
107. Withers MR, McKinney D, Ogutu BR, et al. Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan children. PLoS Clin Trials 2006 1 : e32.
108. Stewart VA, McGrath SM, Walsh DS, et al. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. Vaccine 2006 24 : 6483 6492.
109. Genton B, Al-Yaman F, Betuela I, et al. Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children. Vaccine 2003 22 : 30 41.
110. Okiro EA, Hay SI, Gikandi PW, et al. The decline in paediatric malaria admissions on the coast of Kenya. Malar J 2007 6 : 151.
111. ter Kuile FO, Terlouw DJ, Phillips-Howard PA, et al. Impact of permethrin-treated bed nets on malaria and all-cause morbidity in young children in an area of intense perennial malaria transmission in western Kenya: cross-sectional survey. Am J Trop Med Hyg 2003 68 : 100 107.
112. Kariuki SK, Lal AA, Terlouw DJ, et al. Effects of permethrin-treated bed nets on immunity to malaria in western Kenya II. Antibody responses in young children in an area of intense malaria transmission. Am J Trop Med Hyg 2003 68 : 108 114.
113. Quelhas D, Puyol L, Quinto L, et al. Impact of intermittent preventive treatment with sulfadoxine-pyrimethamine on antibody responses to erythrocytic-stage Plasmodium falciparum antigens in infants in Mozambique. Clin Vaccine Immunol 2008 15 : 1282 1291.
114. Menendez C, Schellenberg D, Macete E, et al. Varying efficacy of intermittent preventive treatment for malaria in infants in two similar trials: public health implications. Malar J 2007 6 : 132.
115. Aponte JJ, Menendez C, Schellenberg D, et al. Age interactions in the development of naturally acquired immunity to Plasmodium falciparum and its clinical presentation. PLoS Med 2007 4 : e242.
116. Greenwood BM, Greenwood AM, Bradley AK, et al. Comparison of two strategies for control of malaria within a primary health care programme in the Gambia. Lancet 1988 1 : 1121 1127.
117. Greenwood BM, David PH, Otoo-Forbes LN, et al. Mortality and morbidity from malaria after stopping malaria chemoprophylaxis. Trans R Soc Trop Med Hyg 1995 89 : 629 633.